MaxCyte, Inc. (NASDAQ:MXCT) CEO Buys $345,170.70 in Stock

MaxCyte, Inc. (NASDAQ:MXCTGet Free Report) CEO Maher Masoud purchased 70,443 shares of MaxCyte stock in a transaction dated Monday, June 10th. The stock was bought at an average cost of $4.90 per share, for a total transaction of $345,170.70. Following the completion of the purchase, the chief executive officer now directly owns 100,000 shares in the company, valued at approximately $490,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Maher Masoud also recently made the following trade(s):

  • On Friday, June 7th, Maher Masoud acquired 29,557 shares of MaxCyte stock. The stock was acquired at an average price of $4.87 per share, with a total value of $143,942.59.

MaxCyte Trading Up 2.1 %

Shares of NASDAQ:MXCT opened at $4.96 on Tuesday. The company has a market capitalization of $517.80 million, a PE ratio of -14.17 and a beta of 1.45. MaxCyte, Inc. has a twelve month low of $2.45 and a twelve month high of $5.55. The firm has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $4.56.

MaxCyte (NASDAQ:MXCTGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative net margin of 83.00% and a negative return on equity of 15.68%. The firm had revenue of $11.34 million during the quarter, compared to the consensus estimate of $7.75 million. As a group, equities research analysts predict that MaxCyte, Inc. will post -0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MXCT. Stephens restated an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a report on Tuesday, April 23rd. BTIG Research dropped their price objective on shares of MaxCyte from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 13th. Finally, William Blair reiterated an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th.

Read Our Latest Stock Report on MXCT

Institutional Trading of MaxCyte

Several institutional investors and hedge funds have recently bought and sold shares of MXCT. Russell Investments Group Ltd. purchased a new position in MaxCyte during the 1st quarter worth $28,000. PNC Financial Services Group Inc. purchased a new position in MaxCyte during the 4th quarter worth $29,000. Victory Capital Management Inc. purchased a new position in MaxCyte during the 3rd quarter worth $31,000. Johnson Investment Counsel Inc. purchased a new position in MaxCyte during the 3rd quarter worth $34,000. Finally, Aigen Investment Management LP purchased a new position in MaxCyte during the 3rd quarter worth $44,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

About MaxCyte

(Get Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Featured Articles

Insider Buying and Selling by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with's FREE daily email newsletter.